Duke University Selects Illumina's Infinium HumanHap550 BeadChip
Complete the form below to unlock access to ALL audio articles.
Illumina, Inc. has announced that Duke University's Center for Human Genetics (CHG) has selected the Infinium HumanHap550 BeadChip for an Autism study of over 1,800 individuals and their families.
The identification of the genes which contribute to complex disease like autism will lead to the development of enhanced diagnostic tools, early detection, and improved health outcomes for patients and their families.
Drs. Margaret Pericak-Vance and John R. Gilbert will lead the Duke CHG team of autism researchers.
According to Dr. Pericak-Vance, "Multiple genes and the interactions of these genes contribute to diseases like autism, making their identification very difficult."
"New technologies and creative thinking are required for the advancement of these projects."
"We are delighted to be working in concert with Illumina and we are excited about the speed, throughput and data completeness we are experiencing with this product."
Dr. Gilbert added, "We are excited to have the opportunity to use Illumina's state of the art, whole-genome genotyping system to accelerate the search for autism risk genes."
